Non/hypo-response to hepatitis B vaccination and influencing factors in HIV-infected patients in the context of different immunization schedules.
10.3760/cma.j.cn112338-20211214-00982
- Author:
Yue CHANG
1
;
Tian YAO
1
;
Jing SHI
1
;
Yuan Ting WU
1
;
Feng YANG
2
;
Chen Li YUAN
3
;
Xiao Yong NIE
3
;
Fu Zhen WANG
4
;
Yong Liang FENG
1
;
Su Ping WANG
1
Author Information
1. Department of Epidemiology, School of Public Health, Shanxi Medical University, Taiyuan 030001, China.
2. Department of Infectious Diseases, The Second Hospital of Yuncheng, Yuncheng 044000, China.
3. Department of STD/AIDS Prevention and Control, Shanxi Provincial Center for Disease Control and Prevention, Taiyuan 030012, China.
4. Department of National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China.
- Publication Type:Randomized Controlled Trial
- MeSH:
Female;
Follow-Up Studies;
HIV Infections/immunology*;
Hepatitis B/prevention & control*;
Hepatitis B Antibodies;
Hepatitis B Surface Antigens;
Hepatitis B Vaccines/administration & dosage*;
Humans;
Immunization Schedule;
Male
- From:Chinese Journal of Epidemiology
2022;43(5):696-701
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To study the non/hypo-response to hepatitis B vaccination in HIV-infected patients, identify the influencing factors and provide evidence for the development of hepatitis B prevention and control strategies and measures for special population. Methods: On the basis of the randomized controlled trial of 20 µg hepatitis B vaccine immunization at 0-1-6 month, 0-1-2-6 month and 60 µg hepatitis B vaccine immunization at 0-1-2-6 month, the HIV-infected patients who completed one-month follow-up after the full course vaccination were selected as study subjects. Quantification of antibody to hepatitis B surface antigen (anti-HBs) in serum samples was performed by using chemiluminescent microparticle immunoassay (CMIA) and demographic characteristics, disease history, HIV infection and treatment status of the study subjects were collected. Statistical analysis was conducted by χ2 test, t test, unconditional logistic regression and interaction analyses. Results: The non/hypo-response rates to hepatitis B vaccination were 34.65% (35/101), 24.49% (24/98) and 10.99% (10/91) in 20 µg group at 0-1-6 month or 0-1-2-6 month and 60 µg group at 0-1-2-6 month (P<0.001), respectively. Logistic regression analysis showed that after controlling for confounding factors, the risk for non/hypo-response was 0.22 times higher in HIV-infected patients receiving 60 µg hepatitis B vaccine at 0-1-2-6 month than in patients receiving 20 µg hepatitis B vaccine at 0-1-6 month (95%CI: 0.10-0.50), the risk for non/hypo-response was higher in men than in women (OR=3.65, 95%CI: 1.88-7.07), and the risk for non/hypo-response was 2.64 times higher in those without hepatitis B vaccination history than in those with hepatitis B vaccination history (95%CI: 1.10-6.32). Moreover, there were multiplicative interactions between immunization schedule and gender (OR=2.49, 95%CI: 1.24-5.00). Conclusion: The non/hypo-response rate to hepatitis B vaccination was significantly lower in HIV-infected patients receiving 60 µg hepatitis B vaccine at 0-1-2-6 month than in those receiving 20 µg hepatitis B vaccine at 0-1-6 month and 0-1-2-6 month. Gender, vaccination schedule and history of hepatitis B vaccination were the influencing factors of the non/hypo-response to hepatitis B vaccination. There was a multiplicative interaction between vaccination schedule and gender, and men receiving 20 µg hepatitis B vaccines had a higher risk for non/hypo-response to hepatitis B vaccination.
